既往纳武利尤单抗治疗对复发/转移性头颈部鳞状细胞癌患者紫杉类治疗反应的影响
这项多中心回顾性比较研究纳入2014至2020年接受紫杉类单药治疗的185例复发/转移性头颈部鳞状细胞癌患者,比较既往接受纳武利尤单抗者(71例)与未接受者(114例)的疗效。结果显示,后纳武利尤单抗组的客观缓解率显著更高(39.4%对26.3%,p=0.03),无进展生存比也显著改善(1.63对1.11,P=0.004),但中位总生存(7.5个月)和中位无进展生存(3.5个月)两组无显著差异。作者认为,既往暴露于纳武利尤单抗后,紫杉类的缓解率和疾病控制率有所提高。
要点
- 后纳武利尤单抗组客观缓解率显著高于对照组(39.4%对26.3%,p=0.03)。
- 后纳武利尤单抗组无进展生存比显著改善(1.63对1.11,P=0.004)。
- 两组中位总生存(7.5个月)和中位无进展生存(3.5个月)无显著差异。
核心结论
- 既往暴露于纳武利尤单抗后,紫杉类的缓解率和疾病控制率有所提高。
- 作者认为,紫杉类单药可作为含铂一线治疗后、纳武利尤单抗之后的良好三线治疗选择。
- 上述结果目前适用于无法获得或可能无法从一线帕博利珠单抗获益的患者。
研究设计与样本
- 多中心回顾性比较研究,纳入2014年至2020年接受紫杉类单药治疗的复发/转移性头颈部鳞状细胞癌患者。
- 共纳入185例患者,分为后纳武利尤单抗组71例和对照组114例。
- 主要终点为两组客观缓解率的比较;次要终点包括疾病控制率、无进展生存、总生存和无进展生存比。
主要发现
- 后纳武利尤单抗组客观缓解率为39.4%,对照组为26.3%(p=0.03)。
- 后纳武利尤单抗组疾病控制率为69%,对照组为50%(P=0.06)。
- 两组中位总生存(7.5个月)和中位无进展生存(3.5个月)无显著差异。
- 后纳武利尤单抗组无进展生存比显著改善(1.63对1.11,P=0.004)。
关键数值与推荐
- 后纳武利尤单抗组客观缓解率39.4%对对照组26.3%(p=0.03)。
- 后纳武利尤单抗组疾病控制率69%对对照组50%(P=0.06)。
- 后纳武利尤单抗组无进展生存比1.63对对照组1.11(P=0.004)。
临床怎么用
- 作者认为,紫杉类单药可作为含铂一线治疗后、纳武利尤单抗之后的良好三线治疗选择。
- 上述结果目前适用于无法获得或可能无法从一线帕博利珠单抗获益的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors are widely used in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). We aimed to describe response rates to taxanes after progression on nivolumab in R/M HNSCC patients. METHODS: In this multicentric retrospective comparative study, we included patients treated with taxane monotherapy from 2014 to 2020. Patients were divided into two groups depending on whether they received nivolumab before taxanes (post-nivolumab group) or not (control group). The primary end-point was objective response rate (ORR) comparison between the two groups. The secondary end-points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and PFS ratio (PFSr=PFS associated with taxanes divided by PFS associated with the previous line of treatment), a survival marker used for comparison of different treatment lines. RESULTS: Between July 2014 and August 2020, 185 patients were included (114 in the control group and 71 in the post-nivolumab group). ORR was significantly higher in the post-nivolumab group (39.4% versus 26.3%, p = 0.03) as was DCR (69% versus 50%, P = 0.06). The median OS (7.5 months) and PFS (3.5 months) were not significantly different in the two groups, whereas PFSr was significantly improved in the post-nivolumab group (1.63 versus 1.11, P = 0.004). CONCLUSION: Response and DCRs with taxanes are improved after prior exposure to nivolumab. Thus, taxane monotherapy could be a good choice as third-line therapy after nivolumab following a platinum-based first line. These results currently apply to patients without access to or potential benefit from first-line pembrolizumab.
引用
- Guiard E, Clatot F, Even C, et al. Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. Eur J Cancer. 2021. PMID: 34743067. doi:10.1016/j.ejca.2021.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。